40 results about "Hl 60 cell" patented technology

The invention discloses a polyoxometalate compound modified by amino acid.The compound has the general formula of Am[B3XMo6O21].nH2O and is prepared through the steps of dissolving Na2MoO4.H2O, Se, As, Sb or Bi oxide, glycine, alanine, histidine, lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine or arginine and KCl in H2O, putting the solution on a magnetic stirrer to be mixed and stirred, adjusting pH of the solution to be 3.4 to 3.6 through HCl, stirring and heating reflux for 0.5-2 hours, conducting cooling and filtering, standing for 1-2 days, and collecting crystals.It is determined through the MTT method that the IC50 value of HL-60 cells is 0.127 microM, the IC50 value of U937 cells is 2.731 microM, the IC50 value of U937 cells is 2.731 microM, and the IC50 value of HUVECs cells is 889.18 microM.The polyoxometalate compound is high in leukemia resistant activity, low in toxicity and low in price.

The invention discloses application of a snake venom-sourced cytotoxin-CTX1 to preparation of an acute leukemia resisting medicine. Experiments prove that the snake venom-sourced cytotoxin-CTX1 can inhibit the proliferation of a leukemia cell, can induce non-viable apoptosis and necrosis of HL-60 cell and KG1a cell, and has obvious medicinal effect in the aspect of leukemia resistance; therefore, the snake venom-sourced cytotoxin-CTX1 can be further developed into anti-tumor medicines with high efficiency, low toxicity and low drug tolerance.

The invention relates to application of water chestnut extract to preparing medicament for treating leukemia, and belongs to the field of medicine. The application of the water chestnut extract to preparing the medicament for treating the leukemia is application of the water chestnut extract to preparing the medicament for inhibiting HL-60 cell proliferation. The water chestnut extract treats the leukemia through inducing HL-60 cell apoptosis. The preparation method for the water chestnut extract has the advantages of simple process, convenient operation, easily grasped technique, and low production cost.

The invention relates to an alpha, beta-unsaturated ketone compound containing thiazole heterocycle, its preparation method and application. The alpha, beta-unsaturated ketone compound containing thiazole heterocycle is shown by the general formula 8, wherein R1 represents hydrogen, methyl or chlorine, R2 represents methyl or chlorine, R3 represents methyl or ethyl, R4 represents hydrogen, phenyl, p-nitro phenyl, p-benzotrifluoride or naphthyl, R5 represents hydrogen, phenyl, p-nitro phenyl, p-benzotrifluoride or naphthyl. The invention also provides the preparation method and application of the compound. The compound has excellent activity for inhibiting GST Pi and activity for inhibiting HL-60 cell growth, and is used for preparing antitumor drugs.

The invention belongs to the field of natural medicinal chemistry and particularly relates to a separation and purification process of natural polysaccharide type anti-inflammatory drug molecules and application thereof. The separation and purification process utilizes water extraction and alcohol sedimentation, protein removal, acid hydrolysis, freeze drying, desalination, affinity chromatography and other methods to purify a polysaccharide fragment having a P-selectin antagonism function from bupleurun chinense. Flow cytometry and protein interaction analysis experiment results show that the bupleurun chinense polysaccharide fragment can effectively prevent the combination between P-selectin and HL-60 cells and the antagonism to the mutual effect of the P-selectin and PSGL-1. The experimental results of a parallel-plate flow chamber and an acute abdominal inflammation mouse model show that the bupleurun chinense polysaccharide fragment has the remarkable inhibitory effect on the HL-60 cells mediated by the P-selectin in a shear stress state and can effectively inhibit leukocytic exudation from the peritoneal fluid of a mouse. The bupleurun chinense polysaccharide fragment prepared by means of the method has good anti-inflammatory activity and has a broad application prospect by serving as a novel anti-inflammatory drug.

The invention provides an aptamer specifically combining acute promyelocyte leukemia HL-60 cells, and further provides a screening method and a clinical application of the aptamer. According to the screening method, six types of aptamers with different sequences are screened, and combining capacity among the aptamers and the acute promyelocyte leukemia HL-60 cells is different. The screening method includes the steps: synthesizing random single-strand DNA (deoxyribonucleic acid) libraries and primers; performing Cell-SELEX screening; performing library amplification; preparing a DNA single-strand library; repeating multiple screening and subduction screening; detecting stability after screening; detecting specificity of the aptamers.

The invention discloses an application of LukS-PV protein in preparation of a medicine for inducing leukemia cell differentiation. The leukemia cell refers to a human promyelocyte leukemia cell HL-60 or human monocyte leukemia cell THP-1. The LukS-PV protein can be massively expressed by using a genetic engineering technology, can be specifically combined with a target cell but not cause the dissolution of the target cell, is small in molecular weight, is easily modified genetically and chemically; and through gene modification, the induction activity is expected to be improved and the toxic and side effects are expected to be reduced; experiment shows that LukS-PV can induce the HL-60 cell to differentiate to marrow monocyte in vitro and induce the THP-1 cell to differentiate to macrophage; LukS-PV can inhibit leukemia cell growth in vivo and reduce infiltration of the leukemia cell to the liver, the spleen and the peripheral blood; therefore, the LukS-PV protein is expected to be developed into a novel leukemia treatment medicine, thereby opening up a novel application field for bacterial toxin.

The invention provides an application of a compound ainsliaidimer A in preparing a nucleolus transcription factor inhibitor medicament. The inventor carries out experiments of detecting activity of NF (nuclear factor)-kappa B by adopting EMSA (electrophoretic mobility shift assay), detecting differences of NF-kappa B in cells by immunochemical luminescent assay, detecting expression of the NF-kappa in ainsliaidimer A acting HL-60 cells by a Western blot method, detecting expression of apoptosis related protein in lymphoma cell CA46 cell after action of the ainsliaidimer A by the Western blot method, detecting influence of the ainsliaidimer A on HL-60 cell secretion VEGF (vascular endothelial growth factor) and the like. Results prove that the ainsliaidimer A has a good inhibition effect to the activity of the NF-kappa B abnormally activated by tumor cells, so that, the compound ainsliaidimer A serving as an active component can be used for preparing a nucleolus transcription factor inhibitor medicament. The medicament can be used as novel application for treating leukemia, autoimmune diseases, renal diseases, heart cerebrovascular diseases, various inflammations, neurodegenerative disorders and eye disorders of animals and humans caused by abnormally activation of the NF-kappa B factor, thereby providing a new method for treating the diseases and disorders, and having higher clinical application value.

The invention discloses a cell line method pyrogen detection method and a kit. The method includes following steps: (1) a pyrogen material standard solution and a to-be-detected sample solution is prepared; (2) the pyrogen material standard solution or the to-be-detected sample solution are respectively added into a HL-60 cell-containing cell culture solution for culture, and cultured cell supernatant is taken; and (3) the content of cytokine IL-6 in the cultured cell supernatant of the step (2). According to the method, human body pyrogen reaction can be simulated, Gram-negative bacterium sourced, Gram-positive bacterium sourced and yeast sourced pyrogen materials can be qualitatively and quantitatively analyzed, sensitivity is high, and the method is simple and easy. The kit includes the pyrogen material standard solution, a cytokine IL-6 detection agent and HL-60 cells, the kit has the advantages of simple operation, capability of pyrogen material qualitative and quantitative analysis, and high sensitivity.

The invention belongs to the technical field of biopharmacy, and relates to a nano preparation method for improving stability of enzyme drugs. The nano preparation is nanoparticles PEG-DGL/En-Aco prepared from cis-acotonic anhydride (Aco), dendritic poly-l-lysine (DGL) and functional polyethylene glycol (NHS-PEG). The entrapment efficiency of the prepared nanoparticles is 71.46+/- 0.31%, the appearance of the nanoparticles is round, and the nanoparticles are spherical; by the nanoparticles, degradation of trypsin to CAT can be relieved, in 72 h, the enzymatic activity of PEG-DGL/CAT-Aco nanoparticles in HL-60 cells is remarkably higher than free CAT, and in an extracellular matrix, the enzymatic activity of crosslinked nanoparticles is gradually increased along with time; by the prepared nanoparticles, the area of cerebral infarction of an animal pattern can be remarkably reduced; and ischemia reperfusion injury can be inhibited obviously, and the nano preparation has potential nerve and blood vessel protection effect. The prepared nanoparticles can be used for preparing drugs for treating stroke.

The invention discloses a detection method for regulating an Hh signal channel to inhibit HL-60 cells. The detection method comprises the steps as follows: proliferation of HL-60 cells among different experiment groups is detected with a kit, the HL-60 cell apoptosis rate of each group is detected through double staining, expression of Hedgehog signal channel components, namely, GLI1 genes and apoptosis genes BCL-2 and BCL-XL, of each experiment group is detected with a semi-quantitative RT-PCR method, and expression of GLI1 protein is detected with an immunofluorescence method. A co-culture mode is established in vitro by use of human acute myelocytic leukemia cell strains HL-60 and HS-5 cells, the interaction of in-vivo leukemia cells and hemopoietic microenvironment around the leukemia cells is simulated, the possible mechanism of the effect and action of the hemopoietic microenvironment on leukemia cell apoptosis is researched, and a theoretical foundation is laid for studying leukemia treatment drugs targeted at blocking the interaction of the hemopoietic microenvironment and the leukemia cells.

The invention discloses a heteropolyvanadate compound which has a molecular formula [NH2(CH3)2]12[(V5O9Cl)6(TATB)8]. A preparation method comprises the following steps: dissolving VCl4 and 4,4,4-triazine-2,4,6-tribenzoic acid into 2ml of N,N-dimethyl formamide and 0.5mL of an acetonitrile solution, and carrying out stirring at room temperature; carrying out crystallization for 40-60 hours at 125-135 DEG C; reducing the temperature, separating a green crystal, carrying out washing, and carrying out room-temperature drying, so as to obtain the heteropolyvanadate compound. In-vitro experiment results show that median inhibitory concentrations of the salt upon cells SMMC-7721, MCF-7, A549 and HL-60 are respectively 0.67[mu] mol/L, 0.44[mu]mol/L, 0.48[mu]mol/L and 2.09[mu]mol/L; and in-vivo experiment results show that the salt is capable of reducing weights of tumors of Hep-A-22 liver cancer tumor-bearing mice.

On a theoretical basis that ultraviolet light (UV) and cobalt chloride simulate low oxygen to induce cell apoptosis, the research uses CoCl2 to simulate a low oxygen environment and uses 280 nm LED UVto irradiate an acute promyelocytic leukemia cell (HL-60 cell), probes into proliferation situation of the HL-60 cell after the HL-60 cell is irradiated by the 280 nm LED UV under the low oxygen environment, discovers that both the 280 nm LED UV and low oxygen inhibit proliferation of the HL-60 cell and induce the cell apoptosis, and the 280 nm LED UV has more obvious proliferation inhibition andapoptosis effects on the cell under the low oxygen condition compared with a normoxic condition. Through irradiating a transplant by the 280 nm LED UV under the low oxygen condition, remaining tumorcells in the transplant are led to apoptosis and necrosis, normal cells can survive normally, so that the ultimate purpose of eliminating remaining tumors is achieved, recurrence rate of leukemia patients after autotransplantation is reduced, and application prospect of the 280 nm LED UV in leukemia autotransplantation purging in vitro is indicated.

The invention discloses a naphthalimide compound fluorescence probe for identifying Ag+ in HL-60 and its preparation method. The naphthalimide compound with a structure of a formula (I) is applied tothe Ag+ detection in the HL-60 cell, and has high Ag+ sensitivity and response value; when it is used as the fluorescence probe, the fluorescence probe has obvious response for Ag+; when Ag+ with different concentrations is detected, the fluorescence probe shows good linear relationship; the fluorescence probe also has good selectivity of Ag+ in the HL-60 cell; the HL-60 suspending cell dyed withnaphthalimide compound is activated by blue light; through observation in a microscope, the cell emits green fluorescence, and the detection method is reliable.

The invention provides novel application of Java brucea fruit oil emulsion injection to the anticancer aspect, in particular to novel application to the anti-leukemia aspect. The invention respectively uses humanized leukemia U937, NB4 and HL-60 cell strains and humanized prostatic carcinoma Du145 cell strains as target cells, and studies the inhabiting effect of the Java brucea fruit oil emulsion injection on the blood system tumor and the urogenital system tumor. The invention discovers that the Java brucea fruit oil emulsion injection has the inhabiting effect on the humanized leukemia HL-60, NB4 and U937cell strains and the humanized prostatic carcinoma Du145 cell strains for the first time, and the inhabiting effect is improved along with the gradual increase of the dosage. In addition, the Java brucea fruit oil emulsion injection can also induce the apoptosis of the humanized leukemia cells, and also has the apoptosis induction effect on the primary dissociated leukemia cells. In addition, the bruceolic oil emulsion injection liquid has low cell toxic effect on peripheral blood lymphocytes of normal persons. The results show that the Java brucea fruit oil emulsion injection has certain potential in the aspect of leukemia treatment, and can provide high-efficiency and low-toxicity medicine for the leukemia treatment.

In the present study, active fractions exhibiting abti-tuberculous activity from the plant Byttneria herbecea (family - Sterculiaceae) is discussed. Methanol extracts of the aerial part of Byttneria herbecea exhibited activity against MtbGS in primary screening of biosynthetic assay. Subsequent fractionation was carried out in organic solvents. Out of all these, two fractions (fraction D and K) are exhibiting inhibitory activity against M.tuberculosis glutamine synthetase activity. These fractions D and K are inhibiting 74% and 44% respectively at 7.5mg/ml concentrations. The determined IC50 value of the fraction K is found to be 4.5 mg/ml from the dose response curve against the purified Mycobacterium tuberculosis Glutamine Synthetase. The major advantage of the present study is that the mode of action of the compound is known, which increases the potential of Byttneria herbecea for becoming an anti-tubercular herbal drug. The IC50 value for M. bovis BCG is 1.56 [mu]g/ml. It was observed that there was no significant effect on proliferation of HL-60 cell line at 10 X MIC levels of the hits. This data indicated that these compounds could be initially considered to be safe.

The invention relates to application of Soimycin A in preparation of an acute myeloid leukemia (AML) radiation and chemotherapy sensitizer. According to the application, in vitro and animal experiments show that the Soimycin A has an effect of improving the radiosensitivity of an AML cell line HL-60 and a chromicmyeloid leukemia (CML) cell line K562, and prove that the Soimycin A has an effect of improving the survival rate of AML mice constructed by HL-60 cell transplantation after chemotherapy. The sensitizer disclosed by the invention has a good application prospect for AML radiation and chemotherapy.

The invention belongs to the field of medicine technology, and relates to a polyketone compound with antitumor activity which is separated from a strain of Ascotricha sp. and a preparation method thereof. The compound has a novel structure, and has substantial effects for inhibiting growth of a human acute promyelocytic leukemia HL-60 cell line and a human leukemia K562 cell line; a fermentation process as well as an extracting and separation method are simple, which are good for carrying out further pharmacological and clinic researches, and developing applications to preparation of medicaments for preventing and treating leukemia.